Copy to clipboard 
J&J MedTech reported 4Q25 orthopedic sales of $2.43 billion, up 5.3% compared to the fourth quarter of 2024. For the full year, the company generated $9.2 billion in orthopedic sales, up 1.1% compared to the prior year.
The company called out increased momentum for orthopedics with growth of 5.3% (3.5% after currency impact), driven by new product launches and better commercial execution. SKU rationalization and VBP impact in China offset some of the gains.
The planned separation of orthopedics is progressing toward a mid-2027 finish, with updates coming from J&J MedTech later in 2026. The company said there has been no distraction from the announcement among its orthopedics team, given the results in the fourth quarter. However, it will be interesting to see subsequent results to determine how much of the fourth quarter lift came from seasonality.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 4Q25 | 4Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| Joint Replacement | $1,006.7 | $941.8 | $64.9 | 6.9% |
| Knees | $432.4 | $398.4 | $34.0 | 8.5% |
| Hips | $438.2 | $418.5 | $19.7 | 4.7% |
| Extremities | $136.1 | $125.0 | $11.1 | 8.9% |
| Spine | $217.8 | $211.5 | $6.3 | 3% |
| Trauma | $719.0 | $679.9 | $39.1 | 5.8% |
| Sports Medicine | $190.5 | $183.8 | $6.7 | 3.7% |
| Orthobiologics | $102.0 | $99.2 | $2.8 | 2.8% |
| Enabling Technology | $21.5 | $19.8 | $1.7 | 8.6% |
| Other | $181.4 | $179.8 | $1.6 | 0.9% |
| Total | $2,439.0 | $2,315.8 | $123.2 | 5.3% |
| Segment | FY25 | FY24 | $ Chg | % Chg |
|---|---|---|---|---|
| Joint Replacement | $3,772.4 | $3,677.6 | $94.8 | 2.6% |
| Knees | $1,587.1 | $1,544.9 | $42.1 | 2.7% |
| Hips | $1,673.7 | $1,638.7 | $35.1 | 2.1% |
| Extremities | $511.6 | $494.0 | $17.6 | 3.6% |
| Spine | $883.5 | $934.1 | ($50.6) | (5.4%) |
| Trauma | $2,791.5 | $2,713.1 | $78.4 | 2.9% |
| Sports Medicine | $712.9 | $726.1 | ($13.2) | (1.8%) |
| Orthobiologics | $343.7 | $350.1 | ($6.4) | (1.8%) |
| Enabling Technology | $76.4 | $71.1 | $5.3 | 7.4% |
| Other | $677.3 | $685.8 | ($8.5) | (1.2%) |
| Total | $9,257.8 | $9,158.0 | $99.7 | 1.1% |
Orthopedic Sales by Geography
| Region | 4Q25 | 4Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $1,520.8 | $1,459.9 | $60.9 | 4.2% |
| OUS | $918.2 | $855.9 | $62.3 | 7.3% |
| EMEA | $427.0 | $392.0 | $34.9 | 8.9% |
| APAC | $293.8 | $280.7 | $13.1 | 4.7% |
| ROW | $197.4 | $183.2 | $14.2 | 7.8% |
| Total | $2,439.0 | $2,315.8 | $123.2 | 5.3% |
| Region | FY25 | FY24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $5,720.3 | $5,689.8 | $30.5 | 0.5% |
| OUS | $3,537.5 | $3,468.3 | $69.2 | 2% |
| EMEA | $1,688.6 | $1,635.1 | $53.6 | 3.3% |
| APAC | $1,149.1 | $1,140.2 | $8.9 | 0.8% |
| ROW | $699.7 | $693.0 | $6.7 | 1% |
| Total | $9,257.8 | $9,158.0 | $99.7 | 1.1% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $24,564.0 | |
| Cost of Sales | $7,968.0 | 32.4% |
| Selling and Admin | $6,753.0 | 27.5% |
| R & D | $4,252.0 | 17.3% |
| Other | $475.0 | 1.9% |
| Net Earnings | $5,116.0 | 20.8% |
J&J MedTech reported 4Q25 orthopedic sales of $2.43 billion, up 5.3% compared to the fourth quarter of 2024. For the full year, the company generated $9.2 billion in orthopedic sales, up 1.1% compared to the prior year.
The company called out increased momentum for orthopedics with growth of 5.3% (3.5% after currency impact), driven by...
J&J MedTech reported 4Q25 orthopedic sales of $2.43 billion, up 5.3% compared to the fourth quarter of 2024. For the full year, the company generated $9.2 billion in orthopedic sales, up 1.1% compared to the prior year.
The company called out increased momentum for orthopedics with growth of 5.3% (3.5% after currency impact), driven by new product launches and better commercial execution. SKU rationalization and VBP impact in China offset some of the gains.
The planned separation of orthopedics is progressing toward a mid-2027 finish, with updates coming from J&J MedTech later in 2026. The company said there has been no distraction from the announcement among its orthopedics team, given the results in the fourth quarter. However, it will be interesting to see subsequent results to determine how much of the fourth quarter lift came from seasonality.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 4Q25 | 4Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| Joint Replacement | $1,006.7 | $941.8 | $64.9 | 6.9% |
| Knees | $432.4 | $398.4 | $34.0 | 8.5% |
| Hips | $438.2 | $418.5 | $19.7 | 4.7% |
| Extremities | $136.1 | $125.0 | $11.1 | 8.9% |
| Spine | $217.8 | $211.5 | $6.3 | 3% |
| Trauma | $719.0 | $679.9 | $39.1 | 5.8% |
| Sports Medicine | $190.5 | $183.8 | $6.7 | 3.7% |
| Orthobiologics | $102.0 | $99.2 | $2.8 | 2.8% |
| Enabling Technology | $21.5 | $19.8 | $1.7 | 8.6% |
| Other | $181.4 | $179.8 | $1.6 | 0.9% |
| Total | $2,439.0 | $2,315.8 | $123.2 | 5.3% |
| Segment | FY25 | FY24 | $ Chg | % Chg |
|---|---|---|---|---|
| Joint Replacement | $3,772.4 | $3,677.6 | $94.8 | 2.6% |
| Knees | $1,587.1 | $1,544.9 | $42.1 | 2.7% |
| Hips | $1,673.7 | $1,638.7 | $35.1 | 2.1% |
| Extremities | $511.6 | $494.0 | $17.6 | 3.6% |
| Spine | $883.5 | $934.1 | ($50.6) | (5.4%) |
| Trauma | $2,791.5 | $2,713.1 | $78.4 | 2.9% |
| Sports Medicine | $712.9 | $726.1 | ($13.2) | (1.8%) |
| Orthobiologics | $343.7 | $350.1 | ($6.4) | (1.8%) |
| Enabling Technology | $76.4 | $71.1 | $5.3 | 7.4% |
| Other | $677.3 | $685.8 | ($8.5) | (1.2%) |
| Total | $9,257.8 | $9,158.0 | $99.7 | 1.1% |
Orthopedic Sales by Geography
| Region | 4Q25 | 4Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $1,520.8 | $1,459.9 | $60.9 | 4.2% |
| OUS | $918.2 | $855.9 | $62.3 | 7.3% |
| EMEA | $427.0 | $392.0 | $34.9 | 8.9% |
| APAC | $293.8 | $280.7 | $13.1 | 4.7% |
| ROW | $197.4 | $183.2 | $14.2 | 7.8% |
| Total | $2,439.0 | $2,315.8 | $123.2 | 5.3% |
| Region | FY25 | FY24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $5,720.3 | $5,689.8 | $30.5 | 0.5% |
| OUS | $3,537.5 | $3,468.3 | $69.2 | 2% |
| EMEA | $1,688.6 | $1,635.1 | $53.6 | 3.3% |
| APAC | $1,149.1 | $1,140.2 | $8.9 | 0.8% |
| ROW | $699.7 | $693.0 | $6.7 | 1% |
| Total | $9,257.8 | $9,158.0 | $99.7 | 1.1% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $24,564.0 | |
| Cost of Sales | $7,968.0 | 32.4% |
| Selling and Admin | $6,753.0 | 27.5% |
| R & D | $4,252.0 | 17.3% |
| Other | $475.0 | 1.9% |
| Net Earnings | $5,116.0 | 20.8% |
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
